The prevalence of chronic kidney disease (CKD) continues to grow, with parallel rises in associated mortality. Despite the development of renin-angiotensin system blockers decades ago, new treatments to halt the progression and reduce the mortality due to CKD remain highly desired.1,2 Fortunately, progress has been made in the form of sodium/glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists,3,4 which have been shown to reduce the risk of kidney failure. Although these significant advances in the pharmacotherapies for CKD have improved the prognosis for such patients, not every patient will benefit from or tolerate these drugs and a substantial proportion remain at risk of progressive kidney function loss.